Vectibix question

[trbiggins]

Been on Vectibex for three months now. Scans after 2 months showed shrinkage in all my liver mets. Plans to go 3 more months and then re-scan. CEAs down to 33 from a previous high in the 300s. My rash seems to be getting better and this worries me. Hopefully it is the meds and not a sign that the vect is not working anymore. Any similar experiences on here?

[bldblu_2]

I have been wondering the same thing. My hub started it on it first of June. Hope somebody chimes in with some info.

[skypup]

I know that the Erbitux rash (also an EGFR inhibitor) tends to improve after six weeks, and has nothing to do with efficacy. Would imagine it's the same for Vectibix.

[mtlimpactfan]

My DW just had 1 round of Vectibix and she now has a full facial rash, no where else on her body. The oncologist did mention that he 'hoped' to see a rash after the first treatment (apparently, its considered as a positive sign as the treatment as some effects) but he also mentioned that the rash would eventually slow down and that does not necessarily mean that the treatment is ineffective. He also mentioned that as a palliative measure, vectibix can usually have a 6-9 mths 'life-extending' impact for patient like my DW.

Anyone with other side effects besides rash? My DW has problems controlling stoma output and we tried everything available out there...

[SkiFletch]

I have no personal experience here, but I read a lot of folks on this forum have their rash get better the longer they're on Erbitux/Vectibix without that fact impacting their treatment success. Seems to this non-dr that the skin just gets used to it.

[WifeOfMike]

trbiggins....
as you started this post, can you do me a favor and change (edit) the spelling on Vectibix- I had a tricky moment trying to find out where to put this post

Vectibix (panitumumab)‎
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

Background The Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy (PRIME) demonstrated that panitumumab–FOLFOX4 significantly improved progression-free survival (PFS) versus FOLFOX4 as first-line treatment of wild-type (WT) KRAS metastatic colorectal cancer (mCRC), the primary end point of the study.

Patients and methods Patients were randomized 1:1 to panitumumab 6.0 mg/kg every 2 weeks + FOLFOX4 (arm 1) or FOLFOX4 (arm 2). This prespecified final descriptive analysis of efficacy and safety was planned for 30 months after the last patient was enrolled.

Results A total of 1183 patients were randomized. Median PFS for WT KRAS mCRC was 10.0 months [95% confidence interval (CI) 9.3–11.4 months] for arm 1 and 8.6 months (95% CI 7.5–9.5 months) for arm 2; hazard ratio (HR) = 0.80; 95% CI 0.67–0.95; P = 0.01. Median overall survival (OS) for WT KRAS mCRC was 23.9 months (95% CI 20.3–27.7 months) for arm 1 and 19.7 months (95% CI 17.6–22.7 months) for arm 2; HR = 0.88; 95% CI 0.73–1.06; P = 0.17 (68% OS events). An exploratory analysis of updated survival (>80% OS events) was carried out which demonstrated improvement in OS; HR = 0.83; 95% CI 0.70–0.98; P = 0.03 for WT KRAS mCRC. The adverse event profile was consistent with the primary analysis.

Conclusions In WT KRAS mCRC, PFS was improved, objective response was higher, and there was a trend toward improved OS with panitumumab–FOLFOX4, with significant improvement in OS observed in an updated analysis of survival in patients with WT KRAS mCRC treated with panitumumab + FOLFOX4 versus FOLFOX4 alone (P = 0.03). These data support a positive benefit-risk profile for panitumumab–FOLFOX4 for patients with previously untreated WT KRAS mCRC. KRAS testing is critical to select appropriate patients for treatment with panitumumab.

I located the entire article HERE (which was a little sneaky of me, as abstracts are easy to find, full articles another story all together
http://annonc.oxfordjournals.org/content/25/7/1346.long

Best wishes to everyone
Vicki

[trbiggins]

Vickie

I changed it just for you.

My situation. Had scans today after three more months of Vectibix. I had mixed results. One lesion grew by 1 cm while another shrank. The rest did not change. Anyways, dc wanted me to stay on Vectibix and he added irenotican. Not excited about going back on chemo, but what can I do? They told me it was not as bad as oxal (oxy) but we will see. Anybody with a similar experience with these two meds, please chime in. Until then, peace.

[mstults]

My Onc is considering Vectibix but he's worried about respiratory issues. I have asthma and history of respiratory issues. Also considering Erbitux but says it has to be given alone and not with Irinotecan.